
































188Effects of percutaneous estradiol–oral
progesterone versus oral conjugated
equine estrogens–medroxyprogesterone
acetate on breast cell proliferation and
bcl-2 protein in healthy womenIn a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone
therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28
days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with oral micronized P (200 mg)
on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate
induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2–oral P with a differ-
ence between therapies approaching significance, the former therapy has a marked impact on the breast whereas
natural percutaneous E2–oral micronized P has not. (Fertil Steril 2011;95:1188–91.2011 by American Society
for Reproductive Medicine.)
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tissuePostmenopausal hormone therapy (HT) has been associated with (1–6). Hormone therapy is not a uniform concept, and various
an increased risk for breast cancer. The risk with combined
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ght ª2011 American Society for Reproductive Medicine, Ppreparations, doses, and regimens of HT may have different
effects (7). Although estrogen is a known mitogen in the breast,
the effects of added progestogens may vary considerably (8–15),
but proliferative responses are seen within 2 months (9–11).
Synthetic progestogens may differ from natural P. In the French
E3N cohort, women taking estrogen in combination with
micronized P were found to have no increase in breast cancer
risk in contrast to women taking estrogen in combination with
synthetic progestogens (16, 17).
In this study we used core needle biopsy to evaluate breast cell
proliferation in healthy postmenopausal women during two different
types of sequential HTs: oral conjugated estrogens plus synthetic
progestogen versus percutaneous E2 plus natural oral micronized P.
A prospective randomized clinical study was performed at the
Karolinska University Hospital, Stockholm, Sweden, between May
2006 and March 2008. Apparently healthy women, aged 44 to 66
years, postmenopausal for at least 12 months, nonsmokers, with
normal mammogram results, and with a body mass index of 18 to
30 kg/m2, were recruited. Follicle-stimulating hormone levels at
screening were >25 IU/L, and E2 levels <90 pmol/L. The washout
period for previous HT users was 3 months.
Exclusion criteria were any breast disease, previous breast sur-
gery, hepatic dysfunction, active gallbladder disease, or history of
thromboembolic disease. Medication with sexual steroids, barbitu-
rates, carbamazepines, phenytoin, glucocorticoids, rifampicin, ci-
metidine, diltiazem, erythromycin, ketoconazole, verapamil, and
quinidine was not permitted.
The study was approved by the independent ethics committee
IRB-2005/762-31 and the Swedish Medical Products Agency
EU-2005/001016-51. All women gave their written informed
consent.0015-0282/$36.00
ublished by Elsevier Inc. doi:10.1016/j.fertnstert.2010.09.062
FSeventy-seven women were assigned randomly to receive
sequential HT with two 28-day cycles of either oral 0.625 mg
conjugated equine estrogens or 2.5 g 0.06% percutaneous E2 gel
(1.5 mg E2), daily, with the addition of respectively 5 mg of oral
medroxyprogesterone acetate (MPA) or 200 mg of oral P, daily,
for the last 14 days of each cycle.
Two percutaneous stereotactic core needle biopsies were per-
formed before treatment and during one of the last 3 days of the
second 28-day treatment cycle, respectively, with the patient under
local anesthesia on a prone table (Lorad, DSM, Danbury, CT) in
the upper outer quadrant of the left breast. The biopsies were par-
affin embedded and sectioned at 5 mm until dewaxed and
immunostained.
Immunostained cells were quantified with use of cell counting
of all available positive and negative cells and fields by two
observers blinded to treatment with the Ki-67/MIB-1 monoclonal
antibody (Bench Mark, Ventana Medical Systems, Illkirch Cedex,
France) (18). The procedure uses an avidin-biotin peroxidase sys-
tem in a Bench Mark staining module, which is a fully computer-
ized system that performs deparaffinization, antigen retrieval,
staining with amplification, and counterstaining in a standardized
and reproducible fashion. Samples containingR50 breast epithe-
lial cells were considered evaluable. Immunostaining for the anti-
apoptotic protein bcl-2 was performed with use of the
commercially available antibody bcl-2 clone 124 (nr 760-4246;
Cell Marque Corp., Rocklin, CA) (19).FIGURE 1
Breast histologic findings from two individual women before (left) and aft
equine estrogens–MPA (top) or percutaneous E2–oral micronized P (bo
antibody. (Original magnification 200.)
Murkes. Correspondence. Fertil Steril 2011.
ertility and SterilityCirculating sex steroid levels and sex hormone-binding globulin
before treatment and on one of the last 3 days of the second 28-day
treatment cycle were quantified by routine hospital methods. Con-
centrations of free T were calculated as described earlier (20).
The detection limits and within- and between-assay coefficients of
variation for T 0.1 nmol/L were 6% and 12%, for sex hormone-
binding globulin 0.2 nmol/L 6.5% and 8.7%, for E2 Spectria
5 pmol/L 7.4% (Orion Diagnostica Oy, Espoo, Finland) and 10.3%,
for E2 Immulite 55 pmol/L 9.3% (Diagnostic Products Corporation,
Los Angeles, CA) and 10.6%, and for P 0.6 nmol/L 8.2% and 9.3%.
Differences between the two treatment groups were assessed
with use of the Mann-Whitney test. For within-group changes
the Wilcoxon signed-rank test was used. Correlations were
assessed by Spearman’s rank correlation test. A P value < .05
was considered statistically significant.
In total, 99 women were tested for eligibility. Twenty-two
women were excluded for not meeting the inclusion criteria.
Seventy-seven women were assigned randomly. A total of 71
women, 37 receiving conjugated equine estrogens–MPA and 34
receiving E2-P, completed the study.
From the 71 women a total of 284 core needle biopsy specimens
were collected. Forty of the 71 women (56%) had assessable sam-
ples at baseline, 53 of 71 (75%) at 2 months, and 35 of 71 (49%)
both at baseline and after 2 months. There were no significant dif-
ferences between treatment groups in mean age, body mass index,er (right) 2months of sequential treatment with either oral conjugated
ttom). Nuclei of proliferating cells staining brown by Ki-67 MIB-1
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1parity, years since menopause, proportion of Ki-67–positive cells
or bcl-2–positive cells, or serum hormone levels at baseline.
After 2 months of treatment, conventional HT, that is, conjugated
equine estrogens–MPA orally, increased proliferation more than
treatment with natural percutaneous E2 in combination with oral P,
at borderline significance (P¼.05). The conventional therapy in-
duced a highly significant increase in proliferation from mean 1%,
median 0.6%, and range 0% to 4% at baseline to mean 10.0%,
median 2.6%, and range 0% to 56% of proliferating normal breast
epithelial cells after 2 months of treatment (P¼.003). In contrast,
treatment with percutaneous E2–oral P did not significantly increase
proliferation (mean 3.1%,median 1.4%, range 0% to 21.5% at base-
linevs.mean 5.8%,median 1.8%, and range 0% to 39%at 2months)
(Fig. 1). This proliferative response of sequential conjugated equine
estrogens–MPA is similar to that of conventional continuous com-
bined treatment found in earlier studies (12, 15, 21, 22) whereas
the natural E2-P therapy did not increase breast cell proliferation
significantly in conformity with previous findings (23). Increased
proliferation duringHTmust be regarded as an unwanted potentially
hazardous side effectwhereas increased apoptosis reasonably is ben-
eficial. The proportion of bcl-2–positive cells was numerically
down-regulated during both therapies approaching significance
(P¼.06) for the natural regimen from mean 49%, median 50%,
and range 0% to 100% before treatment to mean 26%, median
40%, range 0% to 80% at 2 months. The conjugated equine estro-
gens–MPA group values for bcl-2 were mean 46%, median 60%,
range 0% to 90% (baseline) versus mean 27%, median 20%, range
0% to 80% (2 months) without between-groups difference. Down-
regulation became significant for the total material of both
treatments (P¼.01), thus facilitating apoptosis.
In this study conjugated equine estrogens plus MPA orally were
found to increase proliferation more than treatment with natural
percutaneous E2 in combination with oral P, only at borderline sig-
nificance. The power calculations before the study were based on
the assumption of a yield of at least 55% assessable samples both
before and after treatment as found by us earlier with fine-needle
aspiration biopsies (12, 21, 24), resulting in the need for 70
women to fulfill the study. However, with core needle biopsy,
unexpectedly, only 49% of the women had assessable breast
epithelium in biopsies both before and after 2 months of treatment.
Although progestogens have been identified as a potential risk
factor, there are indications of important differences between190 Murkes et al. Correspondencepreparations. In the French E3N cohort there was an absence of
breast cancer risk increase for women taking estrogen in combina-
tion with natural P for at least 5 years of treatment (17, 25). This is
in line with the indication in the current study of a higher
proliferative activity in the breast imposed by oral conjugated
equine estrogens–MPA versus percutaneous E2–micronized P
orally, maintaining an E2 dose of 1.5 mg daily, which is needed
by many women at least in an initial phase of postmenopausal
symptoms.
Not only natural P but also E2 given through the transdermal
route may add to the less-adverse effects on the breast compared
with the conventional oral therapy. In the large General Practi-
tioners Research Database no increase in risk for breast cancer
was observed when opposed estrogens were given transdermally
in contrast to estrogens given orally (26–28).
Although we now have found it clearly less proliferative than
MPA, it is important to stress that P was not found to be antiproli-
ferative in normal breast tissue (9). Furthermore, both MPA and P
have been found to reactivate stem cells with potential for malig-
nancy, in vitro, but the clinical implications of this finding for
women are not elucidated (29). Recently we reported that so far
the only antiproliferative drug in normal breast tissue in vivo is
the anti-P mifepristone, which significantly reduced breast cell
proliferation in premenopausal women (30).
The long-term safety of combined HT especially in the breast
has been discussed vividly over the past decades. The need is
strong to define treatment regimens and alternatives for postmen-
opausal women that have minimal effects on the breast but still
allow effective symptom relief.
The study does not answer whether the estrogenic or progesto-
genic component of HT, or a synergy between both, gives the
more beneficial effect with use of natural treatment. However,
for millions of women with severe climacteric symptoms, we
need to find and evaluate efficient HTs with as low impact on the
breast as possible. The findings of this study suggest that 2 months
of treatment with percutaneous E2 in combination with 14 of 28
days of micronized P has less-adverse effects on normal human
breast proliferation in vivo, and it also seems to facilitate apoptosis.
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